越鞠丸治疗血脂异常机制的网络药理学预测及分子对接验证

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (2157 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the mechanism of Yueju Pills in the treatment of dyslipidemia by network pharmacology and molecular docking. Methods The active components of Yueju Pills were searched by traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) and pertinent literatures, and their target genes were collected, the related gene targets of dyslipidemia were searched and screened by GeneCards, DrugBank and OMIM databases. Cytoscape 3.8.2 software was used to draw the network diagram of “active component-affect target” of Yueju Pills, and protein-protein interaction (PPI) network diagram was draw by STRING platform. The gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis of the drug-disease intersection targets were performed by Metascape database, and molecular docking was carried out by Autodock Vina. Results A total of 56 active components of Yueju Pills were collected, 113 drug-disease intersection targets were obtained, GO and KEGG enrichment analysis results showed that drug-disease intersection targets mainly enriched in cellular response to lipid, cellular response to hormones stimulus, cellular response to lipopolysaccharide and other biological processes, and mainly enriched in AGE-RAGE, TNF, PPAR, insulin, and other related signaling pathways. The results of molecular docking showed that the main active components of Yueju Pills in the treatment of dyslipidemia had strong affinity with the core targets. Conclusion Yueju Pills can correct body lipid metabolism disorder by reducing oxidative damage, promoting lipidemia metabolism, improving liver function, thus playing a role in dyslipidemia, which provides pharmacological basis for future clinical application and research.

Key words： Yueju Pills Dyslipidemia Network pharmacology Molecular docking

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHANG Yan1
	2 LIN Jianguo1 YAO Kuiwu1

Cite this article:

CHANG Yan1,2 LIN Jianguo1 YAO Kuiwu1. Network pharmacological prediction and molecular docking verification of the mechanism of Yueju Pills in the treatment of dyslipidemia#br#[J]. 中国医药导报, 2021, 18(33): 25-30.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I33/25

[1] Kopin L，Lowenstein C. Dyslipidemia [J]. Ann Intern Med，2017，167（11）：ITC81-ITC96.
[2] 陈清杰，杨毅宁.他汀类药物不良反应的研究进展[J].心血管病学进展，2013，34（2）：279-283.
[3] 耿秀超，张雨豪，景佳星，等.中药有效成分对血脂异常作用机制的研究进展[J].中国实验方剂学杂志，2020，26（20）：213-220.
[4] 逄冰，刘文科，郑玉娇，等.基于中医脾瘅理论探讨代谢综合征血脂异常[J].北京中医药，2016，35（6）：573-576.
[5] 黄妍妍，南淑玲.越鞠丸研究进展[J].辽宁中医药大学学报，2019，21（9）：217-220.
[6] 朱尧，刘溦溦，顾宁，等.川芎的活性成分及其心血管系统保护作用研究进展[J].时珍国医国药，2016，27（7）：1701-1704.
[7] 王亭.中药栀子有效成分及药理作用的研究进展[J].中国药师，2015，18（10）：1782-1784.
[8] 邓爱平，李颖，吴志涛，等.苍术化学成分和药理的研究进展[J].中国中药杂志，2016，41（21）：3904-3913.
[9] 潘少斌，孔娜，李静，等.香附化学成分及药理作用研究进展[J].中国现代中药，2019，21（10）：1429-1434.
[10] 孙素芹.越鞠丸加减治疗高脂血症44例临床观察[J].上海中医药杂志，2008，42（1）：35-36.
[11] 张慧茹，张婷婷，许枬，等.基于NMR指导的六神曲成分研究[J].中草药，2019，50（16）：3764-3768.
[12] 王小刚，赵娴，李悦，等.高脂血症发病机制及治疗研究进展[J].辽宁中医药大学学报，2020，22（12）：196-200.
[13] 冯笑予，高嵩山.越鞠丸治疗痰浊阻遏型高脂血症患者疗效观察[J].黑龙江医学，2013，37（9）：796-798.
[14] 孙素芹，虞建华.经方越鞠丸对颈动脉粥样硬化斑块形成患者血清炎性因子的影响[J].实用医药杂志，2016， 33（5）：438-439，443.
[15] 李玉波，郝改梅，贾海骅，等.从肠道菌群多样性探讨越鞠丸对ApoE-/-小鼠血脂的影响[J].中国中医基础医学杂志，2017，23（11）：1559-1563.
[16] Mirsafaei L，Reiner ?譕，Shafabakhsh R，et al. Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment [J]. Plant Foods Hum Nutr，2020，75（3）：307-315.
[17] Kobayashi S. The Effect of Polyphenols on Hypercholesterolemia through Inhibiting the Transport and Expression of Niemann-Pick C1-Like 1 [J]. Int J Mol Sci，2019， 20（19）：4939.
[18] Ward MG，Li G，Barbosa-Lorenzi VC，et al. Stigmasterol prevents glucolipotoxicity induced defects in glucose-stimulated insulin secretion [J]. Sci Rep，2017，7（1）：9536.
[19] Rotllan N，Wanschel AC，Fernández-Hernando A，et al. Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis [J]. Circ Res，2015，116（11）：1744-1752.
[20] Fatima LA，Campello RS，Santos RS，et al. Estrogen receptor 1（ESR1）regulates VEGFA in adipose tissue [J]. Sci Rep，2017，7（1）：16716.
[21] Mcnair E，Qureshi M，Prasad K，et al. Atherosclerosis and the Hypercholesterolemic AGE-RAGE Axis [J]. Int J Angiol，2016，25（2）：110-116.
[22] Prasad K. Low levels of serum soluble receptors for advanced glycation end products，biomarkers for disease state：myth or reality [J]. Int J Angiol，2014，23（1）：11-16.
[23] Tu L，Sun H，Tang M，et al. Red raspberry extract（Rubus idaeus L shrub）intake ameliorates hyperlipidemia in HFD-induced mice through PPAR signaling pathway [J]. Food Chem Toxicol，2019，133：110796.
[24] Scherer T，Lindtner C，O’Hare J，et al. Insulin Regulates Hepatic Triglyceride Secretion and Lipid Content via Signaling in the Brain [J]. Diabetes，2016，65（6）：1511-1520.